Capecitabine pills after chemoradiation for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether taking capecitabine pills on a steady, low schedule after standard treatment can help keep locally advanced head and neck squamous cell cancer from coming back or spreading. You may be eligible if your cancer is stage III–IV and you have finished certain radiation/chemo treatments on time, without current spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is squamous cell cancer (mouth, throat, voice box, or lower throat) and is stage III–IV
- You finished standard treatment such as surgery plus radiation, or chemoradiation, and timing is specific (post-op radiation starts 4–8 weeks after surgery, and enrollment is 4–8 weeks after the last radiation dose)
- No signs on exam/imaging that the cancer is still there locally or that it has spread to distant places
- Your general health is good enough for study pills (ECOG 0–1—able to do most usual activities)
- Your blood, liver, and kidney tests are at safe levels to take capecitabine (including kidney clearance ≥ 50)
- You can take pills by mouth and agree in writing to the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial compares two options—a type of immunotherapy or a chemotherapy pill (capecitabine)—as maintenance treatment after standard chemoradiation for high-risk nasopharyngeal cancer. It aims to see which helps prevent the cancer from coming back.
This trial tests whether giving two rounds of cisplatin chemo along with radiation after surgery can help people with high-risk head and neck squamous cell carcinoma. It is for patients who have already had surgery and whose cancer showed signs of being more aggressive.
This trial tests whether giving the chemotherapy drug capecitabine (Xeloda) before surgery helps shrink head and neck cancers that are not linked to HPV. It is for people with early to moderately advanced disease who have not yet had any treatment.
This study tests whether low-dose capecitabine given after standard treatment can lower the chance that locoregional (nearby) throat cancer returns. It is designed for adults with advanced hypopharyngeal (throat) cancer who have finished curative chemoradiation or surgery and follow-up therapy and show no active cancer on exam.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.